QuidelOrtho Corp (QDEL)
86.59
+0.98 (+1.14%)
USD |
NASDAQ |
Feb 01, 09:50
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.719B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -17.17% |
| Valuation | |
| PE Ratio | 4.606 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.475 |
| Price to Book Value | 1.193 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5609 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 77.65% |
News
Headline
Wire
Time (ET)
SA Breaking News
01/30 07:00
SA Breaking News
01/11 10:41
Yahoo
01/06 16:05
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/15/2023 | 17:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/15/2023 | -- | Results | Q4 2022 | -- | 1.42 | -- | |
| 11/02/2022 | 17:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/02/2022 | -- | Results | Q3 2022 | 1.85 | 0.69 | 167.0% | |
| 08/04/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | 2.34 | 2.68 | -12.69% | |
| 05/04/2022 | 17:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/04/2022 | -- | Results | Q1 2022 | 11.66 | 9.43 | 23.69% |
*Estimated Date/Time
Earnings
Profile
Edit
| QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company's comprehensive product portfolio covers a wide range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and a host of clinical and at-home products to detect COVID-19. |
| URL | https://www.ir.quidelortho.com |
| Investor Relations URL | https://ir.quidel.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 15, 2023 |
| Last Earnings Release | Nov. 02, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 31, 2023.
Fundamentals
| Revenue (TTM) | 3.036B |
| Total Expenses (TTM) | 1.785B |
| Net Income (TTM) | 809.75M |
| Total Assets (Quarterly) | 8.656B |
| Total Liabilities (Quarterly) | 3.860B |
| Shareholders Equity (Quarterly) | 4.795B |
| Cash from Operations (TTM) | 1.037B |
| Cash from Investing (TTM) | -1.681B |
| Cash from Financing (TTM) | 282.74M |
Ratings
Profile
Edit
| QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company's comprehensive product portfolio covers a wide range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and a host of clinical and at-home products to detect COVID-19. |
| URL | https://www.ir.quidelortho.com |
| Investor Relations URL | https://ir.quidel.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 15, 2023 |
| Last Earnings Release | Nov. 02, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| GERM | 829008.0 USD | 3.57% |
| HVAX.TO | 72034.00 USD | 3.28% |
| AOFCX | 83.94M USD | 2.86% |
| MSGCX | 18.64M USD | 2.51% |
| MRCGX | 32.87M USD | 2.47% |
| FHH.F.TO | 385227.0 USD | 2.22% |
| FXH | 33.30M USD | 2.03% |
| TDB3505 | 8.840M USD | 1.73% |
| JSMD | 2.566M USD | 1.35% |
| DJT00675 | 15.20M USD | 1.03% |
| ZGEN.TO | 30623.00 USD | 0.70% |
| FSCFX | 39.35M USD | 0.51% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| QDEL Tweets |